Breaking News

RSV Alert Identifies Increased Respiratory Activity

November 5, 2022 • 1:08 pm CDT
by Fujikama
(Precision Vaccinations News)

The U.S. Centers for Disease Control and Prevention (CDC) published CDCHAN-00479 on November 4, 2022. This Health Alert Network Health Advisory concerns elevated respiratory disease incidence caused by multiple viruses, especially among children.

The CDC confirmed it is tracking levels of respiratory syncytial virus (RSV), influenza, and rhinovirus/enterovirus that are higher than usual for this time of year.

The co-circulation of RSV, influenza viruses, SARS-CoV-2, and others could stress healthcare systems from 2022 to 2023. 

While various flu shot and COVID-19 vaccine options are available, there are no U.S. FDA-approved RSV vaccines as of November 5, 2022.

To prevent RSV-associated hospitalizations, eligible high-risk children should receive palivizumab treatment by AAP guidelines.

In brief, the AAP says children eligible for palivizumab include infants prematurely born at less than 29 weeks gestation, children younger than two years of age with chronic lung disease or hemodynamically significant congenital heart disease, and children with suppressed immune systems or neuromuscular disorders.

Furthermore, a recent announcement indicates the European Union approved Beyfortus® (Nirsevimab) on November 4, 2022.

Beyfortus is a single-dose, long-acting antibody that protects infants through their first RSV season. 

Additional RSV vaccine development and antibody news are posted at PrecisionVaccinations.com/RSV.

Our Trust Standards: Medical Advisory Committee

Share